BCL2L1 and neoplasm: Partial removal of senescent cells using the p16-3MR transgenic mouse model via ganciclovir or treatment with navitoclax (ABT263), an inhibitor of Bcl-2 and Bcl-xL, prolonged survival by 28–35% (10–12 days) from time of tumor implantation.